Vivelle Dot - (0.025,0.0375,0.05,0.075,0.1mg/24hr; Transdermal System)

Generic Name	Estradiol	**Innovator**	Novartis
Dosage	0.025,0.0375,0.05,0.075,0.1mg/24hr; Transdermal System	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Indicated in Treatment of moderate to severe vasomotor symptoms associated with the menopause		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.